Navigation Links
Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Date:4/24/2012

is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit www.novelos.com.INVESTOR CONTACTSJ. Patrick Genn, Vice President of IR

Anne Marie Fields, Senior Vice PresidentNovelos Therapeutics, Inc.

LHAPh: (858) 775-7456

Ph: (212) 838-3777Email: jpgenn@novelos.com

Email: afields@lhai.com, @LHA_IR_PRNovelos Therapeutics, Inc.

Madison, WI
Boston, MA

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FD
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
2. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
3. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
4. Novelos Therapeutics Prices $5.9 Million Public Offering
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today reported ... "We view the results from the Pathology Working ... our planned response to the lorcaserin complete response letter," stated ... working to complete the remaining activities in order to submit ...
... 9, 2011 Enobia Pharma Inc., a clinical stage ... bone disorders, today announced that it has raised US ... shares of its common stock to new pharmaceutical and ... the ongoing development of ENB-0040, Enobia,s enzyme replacement therapy ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results 7Enobia Pharma Raises US $40 Million 2
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... researchers at Mayo Clinic shows that obese patients with ... loss drug sibutramine, while others who lack these genetic ... are published in the October issue of Gastroenterology ... placebo-controlled study, Mayo researchers measured the impact of two ...
... who are part of an Asian-white ,couple face an ... in which both partners are white, according to a new ... University ,School of Medicine. , The researchers also found ... likely than white women with Asian or white partners to ...
... to help save more than 1 million children, Stores ... N.J., Sept. 30 Quarters found in the,bottom of purses, ... living and dying for needy children. The Vitamin Shoppe is ... save the life of a,child., Affecting up to 140 ...
... Turns to Medical Professional to Apply Rigors,of "Evidence-Based Medicine" ... Give Bad Advice About the Best Medicine For Portfolios?, ... expected to base their diagnoses on what the latest ... specific diseases and other,illnesses. Yet most financial advisors do ...
... Hits $178 Million Mark, WHITE PLAINS, N.Y., Sept. ... it has awarded a new Marshall A. Lichtman,Specialized Center ... Becker Professor of Medicine at Stanford University., Dr. ... year for five,years, for a total of $6.25 million. ...
... presidential debate history, a female nominee will take the stage ... new ground in 1984, it has taken 24 years for ... party ticket. On Thursday night, the nation will be watching ... in the vice presidential debate. A revealing study by a ...
Cached Medicine News:Health News:Genes affect weight loss drug effectiveness 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 3Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 4Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 5Health News:The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher 2Health News:Gender is a relative term in politics, MU study finds 2
... MonoPrep LBP Processor is a primary component ... collection, accessioning, processing, sampling, and slide preparation ... management. The MonoPrep LBP Processor produces high-quality ... a broad range of cytology specimen types. ...
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
Medicine Products: